Listen
VARGATEF (nintedanib), tyrosine kinase inhibitor
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
Mar 11 2016
Reason for request
Inclusion
- VARGATEF has Marketing Authorisation in combination with docetaxel in the treatment of adults with locally advanced, metastatic or locally recurrent non-small-cell lung cancer, of adenocarcinoma histology type, after a first line of chemotherapy.
- VARGATEF in combination with docetaxel offers no gain in overall survival or quality of life compared with docetaxel alone.
Clinical Benefit
| Insufficient |
- |
English version
Contact Us
Évaluation des médicaments
